Quantcast

Industry news that matters to you.  Learn more

Archives for March 2014

NeuroVive Pharmaceutical and A1M Pharma Initiate Research Collaboration

NeuroVive Pharmaceutical AB (publ) (STO:NVP) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a collaboration agreement signed on 21 March 2014.

Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target

Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.

Voyager Therapeutics Expands and Strengthens Scientific and Clinical Leadership to Advance Life-Changing Gene Therapies for CNS Disorders

Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), recently announced that Bernard Ravina, M.D., M.S.C.E., has joined the company as Vice President of Clinical Development and Dinah Sah, Ph.D., has been named a permanent member of the leadership team after serving as Interim Senior Vice President of Neuroscience since the company’s launch early this year.

AbsoluteIDQ p180 by Biocrates Life Sciences AG: Cutting-edge Test kit Made in Austria Helps Develop the World’s First Metabolomics-based Blood Test to Predict Alzheimer’s Disease

A US research team has developed the world’s first blood test capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2-3 years in advance. The findings, published in Nature Medicine, were generated using the AbsoluteIDQ p180 test kit by Austrian Biocrates Life Sciences AG.

Pioneering Human Protein Atlas Project Achieves a Major Milestone

Luminex Corporation (NASDAQ: LMNX) recently announced that xMAP® Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project. In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.